PHARMAS CRUSHED BY THE NOVO SPELL
02/01/25 -"Pharmas closed the year with a dreadful performance, itself the reflection of dashed excessive hopes for GLP-1 developments. The unwarranted Novo Nordisk collapse on 19-12 on a marginal miss in its ..."
Pages
55
Language
English
Published on
02/01/25
You may also be interested by these reports :
30/10/25
We remain positive on the group’s development prospects, with electricity demand and prices in the Nordics expected to continue being supported by ...
30/10/25
Following the EBITDA margin upgrade to 7.5-8.5% compared to 5.0-7.0% previously, we have revised upwards our profitability estimates for 2025 to ...
29/10/25
Results remained weak, mirroring the first half, as extended outages at Oskarshamn and lower availability at Loviisa and Forsmark continued to weigh ...
28/10/25
Overall results broadly in line with market expectations, with adjusted EBITDA of €12.0bn, up +4.4% yoy. The Group reaffirmed its full-year guidance ...